IQV IQVIA Holdings Inc.

Doximity (DOCS), which calls itself the leading digital platform for U.S. medical professionals, has seen its stock fall steeply over the past year. Even after a rise over the past three months, the shares sit about 65% below their 52-week high. Management continued its repurchase program, allocating approximately $401 million over the latest twelve months. The test is whether it can keep that up through what it calls its AI investment year.

IQVIA Holdings (IQV) has just priced a US$2b senior notes offering due 2034, a sizable refinancing move that reshapes its debt stack and gives investors fresh information on the company’s funding costs and capital structure. Over the past year IQVIA Holdings has delivered a 42.3% total shareholder return, with the share price up 58.8% over the last 90 days and 6.9% over the past month. The recent 1.1% daily pullback to US$266.42 therefore looks more like a pause after strong momentum than a...

IQVIA Holdings has delivered a strong share-price run recently, which naturally puts more focus on whether the cash it is expected to generate can support the current valuation. With the stock now trading in a different zone to where it sat a year ago, the question is how that move lines up with its underlying cash flows. The share price is up 42.3% over the past year, which puts real pressure on the cash flow story to justify where IQVIA sits today. The company has priced a US$2b senior...

IQV's accelerating organic growth, robust R&DS bookings and expanding AI adoption are strengthening demand visibility and business momentum.

Broyhill Asset Management, a Charlotte-based firm, issued its second-quarter 2026 investor letter, which is available for download here. The Broyhill Equity Composite gained 8.8% in Q2, trailing the MSCI All Country World Index’s 15.1% and the MSCI ACWI Value Index’s 10.8%. For the first half, the Composite returned 2.3%, versus 11.5% for the Index. The […]

NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IQVIA Holdings has outperformed the Health Care sector over the past year, and analysts are highly optimistic about the stock’s prospects.

The past six months have been a windfall for IQVIA’s shareholders. The company’s stock price has jumped 50%, hitting $267.77 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Veeva raises its fiscal 2027 outlook as Vault CRM adoption, R&D growth and Falcon AI momentum support expanding revenue and profitability.

TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

While most software companies were retreating, Paycom made an aggressive and unconventional bet on itself, and the market delivered a verdict that caught even seasoned analysts off guard.

The market is obsessed with a handful of hyperscalers, but the real story might be the thousands of customers you've never heard of.

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including IQVIA (NYSE:IQV) and its peers.

Earlier in the current quarter, IQVIA Holdings reported second-quarter results that topped earnings expectations, with adjusted earnings rising 12.1% year over year and revenue increasing 8.7%, prompting management to raise its 2026 revenue, adjusted EBITDA and adjusted diluted earnings guidance. This upgrade was backed by broad-based demand, strong bookings and contributions from acquisitions, all of which reinforced management’s view that business momentum can be sustained into 2027. With...

The real bet is on what lies beyond this year's performance: a pipeline that could change everything.

IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IQV shares rise 21.7% in a month as data assets, AI-enabled technology and strong cash flow support growth despite liquidity and pricing risks.

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.

While traders pointed to external clinical-trial momentum as a major catalyst, Tempus's own recent guidance raise and narrowing losses provided the underlying backdrop.

VEEV heads into Q2 with Falcon AI, Vault CRM wins and R&D Cloud growth in focus as revenue and EPS estimates point to double-digit gains.

Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.

Despite already outperforming the broader market over the past year, IQVIA continues to enjoy strong backing from Wall Street, with analysts remaining highly optimistic about the stock’s future prospects.

Stock Market Today: The Dow Jones index drops Thursday on Trump's "Economic D-Day" threat on Iran. Walmart dives on earnings.

Well-known pharmaceutical companies such as Merck and Pfizer typically manage this complex process in house. Medpace Holdings which targets oncology, metabolic, cardiology, central nervous system, and anti-infective therapies, raised its 2026 revenue guidance on July’s second-quarter conference call to a midpoint of $2.85 billion, corresponding to a year-over-year increase of 13%. Three months later, Medpace is in the pink: On the heels of second-quarter earnings, the stock is up 14%.

Management raised its full-year forecast, but the market seems to be asking for more than a higher target.

IQVIA shares jump 41.5% in three months as record R&DS bookings, a solid backlog, raised 2026 guidance and share buybacks support sentiment.

In late July and early August 2026, IQVIA Holdings and Medera announced a collaboration pairing IQVIA’s global clinical and commercialization infrastructure with Medera’s Sardocor and Novoheart cardiac gene therapy and human-based drug discovery platforms, alongside IQVIA’s second-quarter results, raised full-year 2026 revenue guidance to between US$17.28 billion and US$17.48 billion, and continued share repurchases. The partnership’s focus on AAV-based cardiac gene therapies and Novoheart’s...

By Exec Edge Editorial Staff IQVIA (NYSE: IQV) and clinical-stage biopharmaceutical company Medera Inc. announced a strategic collaboration aimed at accelerating the development of cardiac gene therapies and human-based drug discovery platforms. Under the partnership, Medera’s Sardocor unit will use IQVIA’s clinical trial, regulatory and commercialization capabilities to advance FDA-cleared, first-in-human gene therapy programs targeting […] The post IQVIA, Medera Partner to Accelerate Developme

ICLR's discounted valuation and $23.4B backlog support upside potential, but falling estimates, weaker margins and execution risks argue for patience.

Fiserv's Q2 revenues miss estimates and margin pressure leads to an earnings miss and cuts in its 2026 growth and profit outlook.

Medpace pairs double-digit growth, record awards and a strong balance sheet with a rich valuation, raising the question of whether the premium already prices in its outlook.

ICON's 33.2% rally is backed by stronger proposal flow, bookings and backlog, but weaker earnings and margins cloud the recovery.

Medpace posted record Q2 awards and a stronger book-to-bill ratio, but can backlog conversion and study timing turn renewed demand into stronger 2027 growth?

IQV's proprietary data platform and expanding clinical research business support growth, but high debt and liquidity risks keep the investment outlook balanced.

IQV shares jump after Q2 earnings beat, record bookings and higher 2026 guidance, but future gains hinge on execution and backlog conversion.

The global healthcare ecosystem in 2026 is leading to a strong recovery in clinical research, with global pharma R&D investment topping $250 billion and the clinical research organization (CRO) market rising to $72 billion at roughly a 9% annual pace. As biopharma companies move capital into complex biologic pipelines, AI-powered trial improvement, and practical data […]

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.

This insider disposed of 16% of direct holdings at $245.21 per share, while maintaining nearly 3,000 shares valued at $740,000.

Sherbet's disposition leaves him with 20,999 directly held shares valued at $5.2 million as IQVIA trades near $238.

Bousbib exercised expiring stock appreciation rights while maintaining about 1.4 million shares in total beneficial ownership.

IQVIA Holdings just saw its internal fair value price target move from US$226.95 to US$232.00, a small reset in the reference point analysts are using. That shift sits against a mixed backdrop, with several firms lifting targets into the low to mid US$200s while at least one prominent analyst has moved to a more cautious US$200 view. As you read on, you will see how these changing targets fit into the evolving IQVIA story and what to watch as new research hits the tape. Analyst Price Targets...

WM beats Q2 earnings estimates as pricing and efficiency lift margins, but softer volumes lead revenues to miss expectations.

VRSK beats Q2 earnings and revenue estimates as subscription growth, Underwriting and Claims gains, and cost discipline supported the results.

IQVIA Holdings (IQV) stock moved after the company reported second quarter results that exceeded analyst estimates, raised full year 2026 revenue and earnings guidance, and expanded its share repurchase program, which highlighted management’s confidence in the business. See our latest analysis for IQVIA Holdings. The earnings beat and guidance raise have come on top of strong recent momentum, with a 90 day share price return of 55.07% and a 1 year total shareholder return of 24.87% suggesting...

The Morning Bull - US Market Morning Update Wednesday, Jul, 29 2026 US stock futures are mixed in early Tuesday trade, with broad S&P 500 contracts slightly in the red while Dow futures edge up. The key driver is the US 10 year Treasury yield hovering around 4.64% as investors brace for this week’s Federal Reserve decision. Markets see roughly a one in three chance of a rate hike now and about a 56% chance by September. At the same time, US durable goods orders for June rose 0.3% and a core...

Shares of clinical research company IQVIA (NYSE: IQV) jumped 12.9% in the morning session after the company reported second-quarter results that surpassed Wall Street's expectations and raised its full-year guidance. The company posted revenue of $4.37 billion, an 8.7% increase year-over-year, which beat estimates of $4.30 billion. Its adjusted earnings per share came in at $3.15, up 12.1% from the previous year and topping the consensus estimate of $3.03.

IQVIA Holdings Inc. (NYSE:IQV) extended its winning streak to a 4th straight session on Tuesday, jumping 13.94 percent to finish at $242.94 apiece after its higher revenue growth outlook and strong second-quarter performance reinforced investor confidence in its growth trajectory. In an updated report, the healthcare technology company said that it was able to grow […]

The headline numbers for IQVIA (IQV) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

IQVIA Holdings Inc (IQV) reports robust financial performance with significant gains in R&D Solutions and AI advancements driving future growth.